The objective of this study was to compare the safety and efficacy of nifedipine in two different formulations (osmotic pump and slow release microgranules) in patients with essential hypertension. A total of 91 patients with mild and moderate essential hypertension were recruited in a randomised, double-blinded trial, to receive a daily dose of 30 mg of nifedipine GITS or nifedipine slow release microgranules for 8 weeks. Patients who did not respond to the above-mentioned dose at week 4 of treatment received an increased dose of 60 mg per day of either drug for the remaining trial period. The primary end point of this study was the variation in mean sitting diastolic blood pressure (SDBP) from base-
Introduction
One of the medications approved by the world health organisation (WHO) guidelines as first-line therapy for the management of hypertensive disease is nifedipine. 1 Common side effects due to its potency and short half-life have led to the investigation and development of sustained-release tablets that deliver a constant dose throughout the day to minimise these adverse effects. Calcium antagonists are potent antihypertensive drugs with different mechanisms of action, the first and most important being the blockage of voltage-dependant calcium channels (type L). [2] [3] [4] They also have anti-atherogenic effects by re-establishing smooth muscle normal endothelial function (direct effect on acetylcholine) thus diminishing oxidative stress and increasing bioavailability of nitric oxide. 5 Finally, the INTACT study showed a reduction in the number of new coronary lesions and less progression in previously diseased coronary segments, attributed to line values to the ones found at week 4 of treatment. The secondary end point was the variation in mean sitting systolic blood pressure (SSBP). Drug tolerability was measured according to incidence of side effects. The results were that both presentations reduced the mean SDBP and SSBP with similar efficacy. Drug side effects were also similar in both formulations. In conclusion nifedipine in slow release microgranules (NMG) is as effective as osmotic pump nifedipine (GITS) in reducing blood pressure with a similar tolerability profile. Journal of Human Hypertension (2002) 16 (Suppl 1), S156-S160. DOI: 10.1038/sj/jhh/1001364 the aforementioned benefits of nifedipine on endothelial function. 6 Currently there are two different presentations for nifedipine: (1) GITS (gastrointestinal therapeutic system) is a sustained-release formulation with a constant dose delivery rate over 16 to 18 h, which guarantees therapeutic plasmatic levels for 24 h with a single daily dose. 7, 8 (2) A formulation containing inert microgranules (NMG), which have a programmed liberation and produce constant plasmatic levels of nifedipine for 24 h, also with a single dosage. 9, 10 Pharmacokinetic studies performed in healthy volunteers, in perfectly controlled settings, have demonstrated both presentations to be bioequivalents. 10 Both GITs and NMG have demonstrated sustained antihypertensive efficacy on several clinical studies 8, [11] [12] [13] [14] [15] with good tolerability and a safe profile. This study was developed to evaluate the effects of both formulations on arterial blood pressure measured with a mercury sphygmomanometer and noninvasive blood pressure monitoring in stage I and II hypertensive patients.
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Methods
A double-blinded, randomised, controlled study was performed in 91 adult patients (male and female) from two different cities in Colombia (Medellín and Barranquilla) who were diagnosed with essential hypertension stages I and II (sitting diastolic blood pressure (SDBP) Ͼ90 mm Hg and Ͻ115 mm Hg), to receive nifedipine 30-60 mg, either in GITS or NMG presentation. Medication was administered once daily, in the morning, after a washout period of 14 days during which any previous antihypertensive medication was suspended.
Criteria for exclusion from the study were: previous history of active coronary disease, II-III degree A-V block, cardiac arrhythmias, heart valve disease, malignant hypertension, diagnosed or probable secondary hypertension, hepatic, gastrointestinal, renal disease, malignancy or autoimmune disease.
Patients who were considered candidates for the study signed informed consent forms before enroling in the trial. Approval was obtained from the institutional review board (IRB) in each participating centre. All requirements stipulated in the Helsinki proclamation and good clinical practice (GCP) regulations were considered and followed.
Study design
This double-blinded, randomised, controlled trial was performed in 91 Colombian patients (from Medellín and Barranquilla) who were diagnosed with essential hypertension stages I and II, to receive 30 to 60 mg of nifedipine (either GITS or NMG) once daily. All patients received placebo for 14 days before receiving the medication in order to withdraw the effects of previous hypertensive medication (washout). After this washout period, the active phase of the study began, randomising patients in two groups (GITs or NMG) for 8 weeks.
After the first 4 weeks of treatment, an office check-up was performed. Those patients whose blood pressure was controlled (SDBP Ͻ90 mm Hg or a Ͼ10 mm Hg decrease in SDBP compared with baseline) continued the same dosage for the remaining trial period. Those patients whose blood pressure was not adequately controlled, received an increased dose of 60 mg/day for the remaining trial period.
Baseline values were obtained at the beginning of the study. Patient follow-up was performed at 4 and 8 weeks of treatment. DBP and systolic blood pressure (SBP) were taken during each visit, in sitting and upright positions using the WHO recommendations and using phase V of the Korotkoff sounds to determine the SDBP. Other variables were also recorded (pulse rate, weight and drug side effects). An ambulatory continuous blood pressure monitoring was taken for every patient at the beginning and ending of the trial period. Laboratory routine tests (hemogram, serum creatinine, BUN, total cholesJournal of Human Hypertension terol, triglycerides, hepatic function tests and urine chemistry) were also taken initially and after completion of treatment.
The primary end point of the study was a change in the SDBP from baseline values to week 4 of treatment. Secondary end points were considered: a change in sitting SBP (SSBP) and/or pulse, a change in standing DBP, standing SBP and pulse from 4 to 8 weeks of treatment and the percentage of patients whose blood pressure was adequately controlled at 4 and 8 weeks of treatment. Patients who responded to treatment were considered to have a SDBP of Ͻ90 mm Hg or a decrease Ͼ10 mm Hg in the SDBP compared with the baseline value.
Evaluation of drug safety and tolerance was performed during check-up visits by clinical record and physical evaluation of any complaint considered to be a drug side effect, specifying its severity and causal relation according to good clinical practice guidelines.
Statistical analysis
A total of 91 patients were calculated as the number necessary to compare both groups and evaluate the study hypothesis (M1 = M2). This sample was calculated with a significance value of 0.05 for both arms, with a statistical potency of 90% to detect a difference of 7 ± 9.9 mm Hg.
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Results
A total of 91 patients were randomised to either group (GITS vs NMG). All patients completed the study (46 patients in group A and 45 patients in group B). Both groups were evenly distributed in both cities and demographic characteristics in both groups were similar (Table 1) .
In group A (GITS) 25 patients (54%) were women compared with 31 patients (68%) in group B (NMG). Mean age value was similar in both groups (51.3 vs 52.9 years).
Efficacy analysis was based on the intention-totreat of the patient population randomised to the trial that completed the 8 weeks of treatment. The variable of primary efficacy was the variation in the SDBP from baseline to fourth week follow up. Both nifedipine formulations were equally effective in decreasing the SDBP after 4 weeks of treatment (P Ͻ 0.0001). The MSDBP (mean sitting DBP) was reduced from 99.38 mm Hg initially to 87.66 mm Hg at 4-week follow-up with the GITS formulations. Similar results were obtained with the NMG formulations (99.79 mm Hg initially vs 89.9 mm Hg at 4 weeks) without any significantly statistical difference between both medications (P = 0.143). The MSSBP (mean sitting SBP) was reduced from 150.28 mm Hg at baseline to 135.3 mm Hg at 4 weeks of treatment with the GITS formulations, and from 152.93 mm Hg to 136.91 mm Hg with the NMG formulation (Tables 2 and 3) . When the daily dose of nifedipine was increased to 60 mg, there was a larger reduction in the MSDBP and MSSBP values, but without any statistical significance when compared with the group that received a fixed daily dose of 30 mg throughout the 8 weeks of treatment.
There were no differences in the pulse rate with nifedipine treatment in either group. Response rate was similar in both groups at week 4, 82% GITS group vs 75.5% NMG group, week 8, 82% GITS group vs 73% NMG group (Table 4) .
Safety and tolerability
The analysis of safety and tolerability was done in the group of patients with intention-to-treat that were randomised in the study and who received at least one single dose of active treatment (not placebo). No significant alterations were found in the patients' laboratory values, electrocardiogram or chest X-rays. Eight patients in the GITS group reported eight adverse effects compared with nine patients in the NMG group who reported 13 side effects related to the drug use. The most common side effect was headache. All side effects reported were considered mild in severity and no single patient abandoned the treatment because of them. The increased dosage of nifedipine (60 mg) had an increase in the appearance of adverse effects but was well tolerated in many of the patients (Table 5 ). 
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Discussion
This double-blinded, randomised trial was designed to compare the safety and efficacy of two different nifedipine formulations (GITS and NMG) in Colombian patients with essential hypertension stages I-II, in two different cities (Medellín 1532 m, and Barranquilla 100 m above sea level). In the variable of primary efficacy (decrease in MSDBP), both presentations were effective in controlling blood pressure and reducing MSDBP without significant statistical differences. The same occurred with MSSBP values. The percentage of patients who
Journal of Human Hypertension responded to the medication was 82.5 in the GITS group and 75.5 in the NMG group. This percentage of patients who responded to treatment slightly increased when 60 mg/day of nifedipine was used. Adverse reactions were similar in both groups, most of them related to vasodilation (headache, oedema, flushing), and are similar to the ones reported in other nifedipine trials. The increased dose of 60 mg per day did not affect tolerability to the medication. It may be possible that adverse effects are more frequent in women and related to altitude (sea level), considering that the sympathetic nervous system affects endothelial vasodilation in a direct way.
